FindTrial
Sign In

Comparison of the Middle molecule clearance in patients of chronic kidney disease (CKD) undergoing Renal Replacement Therapy by different modalities

Comparison of the Fibroblast Growth Factor (FGF -23) and Beta 2 microglobulin (β2M) levels in patients of chronic kidney disease (CKD) undergoing Renal Replacement Therapy (Haemodialysis vs Hemodiafiltration)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046910
Enrollment
30
Registered
2022-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N17-N19- Acute kidney failure and chronic kidney disease

Interventions

Intervention1: Haemodiafiltration: To check for middle molecule clearance in Haemodiafiltration vs haemodialysis in CKD stage 5 patients. Patients would be provided Renal replacement therapy by each o

Sponsors

DGAFMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Eligible adults of CKD 5D aged at least 18 years of age who have been initiated on any one of the two modalities of dialysis Individual should have functional AV fistula with blood flow more than 300 ml/min

Exclusion criteria

Exclusion criteria: Patients not having AV Fistula as vascular access in HDF and HD group 2. Patients not giving written informed consent will be excluded.

Design outcomes

Primary

MeasureTime frame
Levels of FGF-23 and Beta 2 microglobulinTimepoint: At Initiation of dialysis modality(0 week) and six(6) weeks—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactParikshit Chauhan

AFMC

parikshitchauhan78@yahoo.co.in9872629226

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026